Can a triple therapy shrink untreatable liver tumors?

NCT ID NCT07724951

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study looks at whether combining the targeted drug donafenib with an immunotherapy drug and a liver-directed procedure (either chemoembolization or infusion chemotherapy) can help people with unresectable hepatocellular carcinoma — liver cancer that cannot be removed by surgery. Researchers will review medical records from about 400 patients treated at multiple hospitals to see how long the cancer stays under control and how safe the combination is. The goal is to find a better first-line treatment for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donafenib plus an anti-PD-1/L1 monoclonal antibody plus either transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC)
What this could lead to: If successful, this combination approach could offer a more effective first-line treatment option for people with unresectable liver cancer, potentially extending survival.
What could go wrong: This is a retrospective study, not a controlled trial, so results may be influenced by patient selection. The combination also carries risks of side effects from chemotherapy, immunotherapy, and liver-targeted procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sun Yat-sen Memorial Hospital

Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China
Yunnan Cancer Hospital

Kunming, Yunan, China
Zhong Shan Hospital Fudan University

Shanghai, Shanghai Municipality, China
Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.